| COVID-19 Clinical Research Studies | Lifetime | 32 | GR 1 | 99.75 |
| Peptidase Inhibition and Analysis | Lifetime | 44 | GR 1 | 99.73 |
| Bone health and treatments | Lifetime | 30 | GR 1 | 99.78 |
| Multiple Myeloma Research and Treatments | Lifetime | 27 | GR 1 | 99.79 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 82 | GR 1 | 99.57 |
| Protein Degradation and Inhibitors | Lifetime | 36 | GR 1 | 99.62 |
| Cancer Treatment and Pharmacology | Lifetime | 130 | GR 1 | 99.58 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 61 | GR 1 | 99.39 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 47 | GR 2 | 99.12 |
| Hemoglobinopathies and Related Disorders | Lifetime | 122 | GR 1 | 98.85 |
| Long-Term Effects of COVID-19 | Lifetime | 318 | GR 4 | 97.35 |
| Bone Metabolism and Diseases | Lifetime | 164 | GR 1 | 98.80 |
| COVID-19 and healthcare impacts | Lifetime | 296 | GR 1 | 96.03 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 531 | GR 3 | 98.60 |
| Bone and Joint Diseases | Lifetime | 220 | GR 2 | 98.16 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 433 | GR 2 | 97.67 |
| Hematological disorders and diagnostics | Lifetime | 178 | GR 2 | 97.34 |
| Ubiquitin and proteasome pathways | Lifetime | 587 | GR 2 | 97.52 |
| Iron Metabolism and Disorders | Lifetime | 603 | GR 5 | 96.64 |
| Blood disorders and treatments | Lifetime | 684 | GR 1 | 93.29 |
| SARS-CoV-2 detection and testing | Lifetime | 747 | GR 3 | 91.09 |
| Cancer Mechanisms and Therapy | Lifetime | 893 | GR 4 | 92.24 |
| Osteomyelitis and Bone Disorders Research | Lifetime | 140 | GR 1 | 90.06 |
| Chemokine receptors and signaling | Lifetime | 804 | GR 4 | 91.02 |
| GDF15 and Related Biomarkers | Lifetime | 899 | GR 13 | 74.20 |
| COVID-19 Clinical Research Studies | 2021-2025 | 23 | GR 1 | 99.76 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 31 | GR 1 | 99.76 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 9 | GR 1 | 99.85 |
| Peptidase Inhibition and Analysis | 2021-2025 | 12 | GR 1 | 99.56 |
| Protein Degradation and Inhibitors | 2021-2025 | 12 | GR 1 | 99.64 |
| Immunotherapy and Immune Responses | 2021-2025 | 62 | GR 1 | 98.90 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 76 | GR 2 | 98.92 |
| Ubiquitin and proteasome pathways | 2021-2025 | 75 | GR 1 | 95.93 |
| Cancer Treatment and Pharmacology | 2021-2025 | 115 | GR 1 | 97.69 |
| Animal Virus Infections Studies | 2021-2025 | 155 | GR 1 | 95.24 |
| Long-Term Effects of COVID-19 | 2021-2025 | 556 | GR 8 | 95.16 |
| Bone health and treatments | 2021-2025 | 82 | GR 2 | 94.85 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 334 | GR 2 | 94.51 |
| Cancer Mechanisms and Therapy | 2021-2025 | 97 | GR 2 | 93.32 |
| SARS-CoV-2 detection and testing | 2021-2025 | 479 | GR 3 | 91.87 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 171 | GR 5 | 93.75 |
| COVID-19 and healthcare impacts | 2021-2025 | 958 | GR 6 | 88.86 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 492 | GR 4 | 91.19 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 654 | GR 4 | 86.90 |
| Cancer therapeutics and mechanisms | 2021-2025 | 452 | GR 2 | 82.00 |
| Hematological disorders and diagnostics | 2021-2025 | 265 | GR 2 | 73.78 |
| Chemokine receptors and signaling | 2021-2025 | 349 | GR 1 | 68.68 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 594 | GR 8 | 64.41 |
| Phytochemical compounds biological activities | 2021-2025 | 616 | GR 1 | 58.02 |
| Natural Product Synthesis and Anticancer Bioactivity | 2021-2025 | 164 | GR 2 | 45.63 |
